Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:30:53.409Z.
Calculation as of: 2026-10-06T21:30:53.409Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6e30e9273cc74abd864e2fca08a62f10ee0154e442432ff18a73c00261064cea
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$471.57M
EV/EBITDA Ratio
8036.17x
TTM Avg
8683.24x
3Y Avg
8683.24x
5Y Avg
8683.24x
Market Cap
$472.23M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$469.12M
EV/EBITDA Ratio
N/A
TTM Avg
202.61x
3Y Avg
202.61x
5Y Avg
202.61x
Market Cap
$475.91M
EV/EBITDA Ratio
N/A
TTM Avg
5.88x
3Y Avg
17.52x
5Y Avg
17.52x
Market Cap
$483.54M
EV/EBITDA Ratio
10.41x
TTM Avg
7.79x
3Y Avg
5.90x
5Y Avg
5.85x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arvinas, Inc. (ARVN) | $471.65M | N/A | N/A | N/A | N/A |
| Cerus Corporation (CERS)vs › | $471.57M | 8036.17x | 8683.24x | 8683.24x | 8683.24x |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.23M | N/A | N/A | N/A | N/A |
| Alpha Teknova, Inc. (TKNO)vs › | $469.12M | N/A | 202.61x | 202.61x | 202.61x |
| Kamada Ltd. (KMDA)vs › | $467.90M | 10.44x | 9.91x | 9.78x | 16.95x |
| Contineum Therapeutics, Inc. (CTNM)vs › | $475.91M | N/A | 5.88x | 17.52x | 17.52x |
| Sight Sciences, Inc. (SGHT)vs › | $465.75M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $483.54M | 10.41x | 7.79x | 5.90x | 5.85x |
| Evolus, Inc. (EOLS)vs › | $486.01M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $452.54M | 23.08x | 16.39x | 15.03x | 16.69x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
